跳至主要内容
临床试验/CTRI/2025/09/094862
CTRI/2025/09/094862招募中不适用

Safety and Efficacy of Regional Citrate Anticoagulation in Pediatric CRRT

Dr Yashkumar Prajapati1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2025年9月29日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
10
试验地点
1
主要终点
To determine proportion of patients showing survival of CRRT circuit.

研究概览

简要总结

Continuous Renal Replacement Therapy (CRRT) is widely used in critically ill children for various indications such as acute kidney injury and other variation conditions. Anticoagulation is essential to maintain circuit function during CRRT, with regional citrate anticoagulation (RCA) and systemic heparin being the primary methods. RCA is preferred in many cases due to lower bleeding risk and longer circuit life, especially in adult patients. However, evidence on its use in children is limited. This study aims to evaluate the safety and efficacy of RCA in pediatric patients undergoing CRRT at this center.

研究设计

研究类型
Observational

入排标准

年龄范围
1.00 Month(s) 至 18.00 Year(s)(—)
性别
All

入选标准

  • Pediatric patient who require continuous renal replacement therapy (CRRT) with regional citrate anticoagulation (RCA).

排除标准

  • (1) Patients are already on systemic anticoagulation, such as heparin or warfarin.
  • (2) Known inherited or acquired disorders of calcium or citrate metabolism, e.g. primary hypoparathyroidism, mitochondrial citrate transport defects.

结局指标

主要结局

To determine proportion of patients showing survival of CRRT circuit.

时间窗: At 48 hours

次要结局

  • To determine survival of CRRT circuit without citrate accumulation.(At 72 hours)
  • To measure incidence of severe bleeding, electrolyte imbalance, metabolic acidosis.(Within 72 hours)

研究者

发起方
Dr Yashkumar Prajapati
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Yashkumar Prajapati

INDRAPRASTHA APOLLO HOSPITAL

研究点 (1)

Loading locations...

相似试验